Social Media Ideas for Lly

Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

This New Zepbound Study Could Be Great News for Eli Lilly Investors

The high-flying healthcare leader looks unstoppable right now.

Eli Lilly: Quiet Momentum Builds Into Q3 Earnings, But Watch The Chart Too

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

Lilly wins EU backing for Foundayo weight-loss pill

Stock Split Watch: Is Eli Lilly Next?

The stock has soared 25% in six months.

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

LVL

LVL Anonymous (not verified) Thu, 09/03/2026 - 12:46 field_thread_url https://cafepharma.com/boards/threads/lvl.715758/ board name...

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a...

Eli Lilly: Impressive Growth, Questionable Valuation

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Lilly’s latest China drug deal; Immunovant’s setback in lupus

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA...

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

The drug giant added to its immunotherapy portfolio.

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate...

Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock

This company is a leader in a high-growth field.

GLP-1s: Still Early In The Growth Story

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Can anyone stop Eli Lilly’s progress in the weight loss market?

Eli Lilly-backed TRex Bio closes day flat after IPO